These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6103063)

  • 21. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abolition of oxotremorine effects by L-DOPA pretreatment.
    Korczyn AD; Eshel Y
    Neuropharmacology; 1979 Jul; 18(7):601-3. PubMed ID: 573869
    [No Abstract]   [Full Text] [Related]  

  • 23. The effects of a hypothalamic peptide factor, MIF and its cyclic analog on tolerance to haloperidol in the rat.
    Bhargava HN
    Life Sci; 1981 Jul; 29(1):45-51. PubMed ID: 6115301
    [No Abstract]   [Full Text] [Related]  

  • 24. Structural specificity of MIF-1 and Tyr-MIF-1 in augmenting GABA-stimulated benzodiazepine receptor binding.
    Miller LG; Kastin AJ; Roy RB; Gaver A; Fischman AJ; Horvath A
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):365-8. PubMed ID: 2908009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone-like protective effect of MIF-1 (Pro-Leu-Gly-NH2) on hemorrhagic shock.
    Krause W; Nieber K; Ehrlich A; Bienert M; Oehme P
    Pharmazie; 1984 May; 39(5):352-3. PubMed ID: 6147863
    [No Abstract]   [Full Text] [Related]  

  • 26. MIF-1 (Pro-Leu-Gly-NH2) decreases activity in Siamese fighting fish (Betta splendens).
    Brown MM; Sardenga PB; Olson GA; Delatte SW; Olson RD
    Pharmacol Biochem Behav; 1984 Apr; 20(4):629-30. PubMed ID: 6145165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Habituation of the head-poke response: effects of an amphetamine-barbiturate mixture, PLG and fenfluramine.
    Koek W; Slangen JL
    Psychopharmacology (Berl); 1981; 72(3):251-6. PubMed ID: 6111822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) and related peptides to mu 1 and mu 2 opiate receptors.
    Zadina JE; Paul D; Gergen KA; Ge LJ; Hackler L; Kastin AJ
    Neurosci Lett; 1996 Aug; 215(1):65-9. PubMed ID: 8880755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some observations on the pharmacological activity of MIF (Pro-Leu-Gly-NH2).
    Turnbull MJ; Wheeler H
    J Pharm Pharmacol; 1980 Nov; 32(11):803-4. PubMed ID: 6110739
    [No Abstract]   [Full Text] [Related]  

  • 30. Suppression of ACTH secretion by synthetic MSH-release inhibiting factor Pro-Leu-Gly-NH2 in Addison's disease.
    Voigt KH; Fehm HL; Lang RE; Beinert KE; Pfeiffer EF
    Horm Metab Res; 1977 Mar; 9(2):150-2. PubMed ID: 16818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of melanotrophin release inhibiting factor (MIF) and cyclo (Leu-Gly) on the tolerance to morphine-induced antinociception in the rat: a dose-response study.
    Bhargava HN
    Br J Pharmacol; 1981 Apr; 72(4):707-14. PubMed ID: 6116510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and conformational study of two L-prolyl-L-leucyl-glycinamide analogues with a reduced peptide bond.
    Vander Elst P; Elseviers M; De Cock E; Van Marsenille M; Tourwé D; Van Binst G
    Int J Pept Protein Res; 1986 Jun; 27(6):633-42. PubMed ID: 2875969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neurotropic properties of fluphenazine].
    Liubimov BI; Raevskiĭ KS; Ostrovskaia RU; Barkov NK; Krolevets GN
    Farmakol Toksikol; 1971; 34(3):287-90. PubMed ID: 5106035
    [No Abstract]   [Full Text] [Related]  

  • 34. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
    Cox B; Kastin AJ; Schnieden H
    Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of peptides on tolerance to the cataleptic and hypothermic effects of morphine in the rat.
    Bhargava HN
    Neuropharmacology; 1981 Apr; 20(4):385-90. PubMed ID: 6117032
    [No Abstract]   [Full Text] [Related]  

  • 36. Selective effects of alpha-MSH and MIF-1 on the blood-brain barrier.
    Sankar R; Domer FR; Kastin AJ
    Peptides; 1981; 2(3):345-7. PubMed ID: 6117842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of melanostatin on the central nervous system].
    Chepurnova NE; Borzenkov VM; Chepurnov SA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (2):36-42. PubMed ID: 6132624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amantadine antagonism of oxotremorine effects.
    Eshel Y; Korczyn AD
    J Neural Transm; 1979; 46(1):79-83. PubMed ID: 574156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible involvement of the antiserotoninergic and antihistaminergic activity in the anticataleptogenic effect of EGYT-2509.
    István G; Gyertyán I; Gigler G; Somogyi E; Petöcz L
    Acta Physiol Hung; 1990; 75 Suppl():119-20. PubMed ID: 1973556
    [No Abstract]   [Full Text] [Related]  

  • 40. The new antidepressant pirlindole. A comparison with imipramine and tranylcypromine.
    Martorana PA; Nitz RE
    Arzneimittelforschung; 1979; 29(6):946-9. PubMed ID: 314808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.